Q-omics provides the consensus-scored KIAA0100 profile across patient tissues and cancer cell-line models. KIAA0100 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KIAA0100 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, KIAA0100 protein abundance shows 28,866 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where KIAA0100 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KIAA0100 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KIAA0100 survival associations across molecular data types. KIAA0100 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (10) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KIAA0100 RNA expression–survival associations across cancer types. High KIAA0100 expression shows unfavorable associations in ACC, LIHC, UVM, CESC and OV, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KIAA0100 RNA expression.
This table summarizes KIAA0100 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 10. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KIAA0100. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KIAA0100 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, HNSC, CHOL and STAD. The LIHC box plot shows higher KIAA0100 RNA expression in tumor versus normal tissue (log2 FC = +2.143, t-test p < 0.001).
This table shows molecular features associated with KIAA0100 in patient tissues and cancer cell lines. In patient samples, KIAA0100 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KIAA0100 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
